Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Oct 23;398(10310):1482-1484.
doi: 10.1016/S0140-6736(21)02096-1. Epub 2021 Oct 4.

Immunological responses to SARS-CoV-2 vaccines in kidney transplant recipients

Maria Prendecki  1 , Tina Thomson  2 , Candice L Clarke  1 , Paul Martin  1 , Sarah Gleeson  2 , Rute Cardoso De Aguiar  2 , Helena Edwards  2 , Paige Mortimer  2 , Stacey McIntyre  3 , Donald Mokreri  4 , Alison Cox  5 , Graham Pickard  5 , Liz Lightstone  1 , David Thomas  1 , Stephen P McAdoo  1 , Peter Kelleher  6 , Michelle Willicombe  7 ; Imperial Renal COVID-19 vaccine study group in collaboration with the OCTAVE Study Consortium
Affiliations
Comment

Immunological responses to SARS-CoV-2 vaccines in kidney transplant recipients

Maria Prendecki et al. Lancet. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

PK and MW have received support to use the T-SPOT Discovery SARS-CoV-2 by Oxford Immunotec. MP, TT, and CLC contributed equally. Members of the Imperial Renal COVID-19 vaccine study group are listed in the appendix (pp 25–26). All other authors declare no competing interests.

Figures

Figure
Figure
Immunological responses to SARS-CoV-2 vaccination in kidney transplant recipients Data are shown as median with IQR. Statistical analysis is by Mann-Whitney test (A) or Kruskall-Wallis test with Dunns post-hoc correction (B). (A) Kidney transplant recipients who received BNT162b2 had significantly higher anti-S concentrations. For infection-naive patients median anti-S titre was median 58 BAU/mL (IQR 7·1–722) for BNT162b2 and 7·1 BAU/mL (7·1–39) for ChAdOx1 (p<0·0001). In patients with previous infection, median anti-S titre was 2350 BAU/mL (628–5680) for BNT162b2 compared with 622 BAU/mL (151–1706) for ChAdOx1 (p<0·0001). The black dotted line represents 7·1 BAU/mL, the cutoff for a positive result. (B) Infection-naive patients who received BNT162b2 had a greater T-cell response compared with patients who received ChAdOx1, with 14 SFU/106 PBMCs (4–32) for BNT162b2 and 4 SFU/106 PBMCs (0–12) for ChAdOx1 (p=0·019). Infection-naive HCWs receiving BNT162b2 and ChAdOx1 had significantly greater responses compared with patients having the corresponding vaccine, with a median 63 SFU/106 PBMCs (21–132; p=0·0003) for BNT162b2 and 68 SFU/106 PBMCs (30–162; p<0·0001) for ChAdOx1. Data points of SFU/106 PBMCs are represented as 0·1 for visualisation on a log scale. The black dotted line represents the threshold for a positive enzyme-linked immunospot, 40 SFU/106 PBMCs, which was calculated from unvaccinated infection-naive HCWs. Anti-S=antibodies to spike protein. HCW=health-care worker. PBMC=peripheral blood mononuclear cells. SFU=spot forming units.
See this image and copyright information in PMC

Comment on

References

    1. Benotmane I, Gautier-Vargas G, Cognard N, et al. Weak anti-SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients. Kidney Int. 2021;99:1487–1489. - PMC - PubMed
    1. Bertrand D, Hamzaoui M, Lemée V, et al. Antibody and T cell response to SARS-CoV-2 messenger RNA BNT162b2 vaccine in kidney transplant recipients and hemodialysis patients. J Am Soc Nephrol. 2021;32:2147–2152. - PMC - PubMed
    1. Boyarsky BJ, Werbel WA, Avery RK, et al. Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA. 2021;325:2204–2206. - PMC - PubMed
    1. Cucchiari D, Egri N, Bodro M, et al. Cellular and humoral response after mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients. Am J Transplant. 2021;21:2727–2739. - PMC - PubMed
    1. Marion O, Del Bello A, Abravanel F, et al. Safety and immunogenicity of anti-SARS-CoV-2 messenger RNA vaccines in recipients of solid organ transplants. Ann Intern Med. 2021 doi: 10.7326/M21-1341. published online May 25. - DOI - PMC - PubMed

Substances